Literature DB >> 35115

Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients.

R C Smith, J Crayton, H Dekirmenjian, D Klass, J M Davis.   

Abstract

Blood levels of butaperazine were measured in schizophrenic patients who were chronic nonresponders to their psychotropic medication. The blood levels were compared with those in patients who had shown a better clinical response to this neuroleptic. Nonresponders had two to seven times lower levels of butaperazine in plasma and RBCs after a single dose or chronic dosing. Some of the patients later treated with thioridazine or haloperidol had lower plasma levels of these neuroleptics also. No significant differences were found between nonresponders and relative responders in either the alpha- or beta-phase half-life of butaperazine in plasma and RBCs after administration of a single dose of the drug. Butaperazine and thioridazine levels were not related to previously administered amounts of neuroleptic drugs. These findings do not support the hypothesis that low blood levels are the result of faster systemic metabolism of the drug after it reaches the central circulation. Our results suggest that low blood levels of neuroleptics may be one important factor in the poor clinical response of some chronic schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 35115     DOI: 10.1001/archpsyc.1979.01780050089011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  11 in total

1.  [Fatal poisoning by protriptyline and haloperidol following an extreme overdose].

Authors:  G Fechner; I Magureanu; R Aderjan; G Schmidt
Journal:  Z Rechtsmed       Date:  1986

2.  Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

Authors:  L T Kucharski; P Alexander; L Tune; J Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

3.  Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.

Authors:  R Rimón; I Averbuch; P Rozick; L Fijman-Danilovich; T Kara; H Dasberg; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

4.  Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients.

Authors:  R C Smith; C A Tamminga; J W Crayton; H Dekirmenjian; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

5.  A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.

Authors:  B Wistedt; A Jørgensen; D Wiles
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  A quantitative magnetic resonance imaging study of patients with schizophrenia.

Authors:  Y Kawasaki; Y Maeda; K Urata; M Higashima; N Yamaguchi; M Suzuki; T Takashima; Y Ide
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

7.  Antiemetic effect of haloperidol in the dog as related to plasma level and dose.

Authors:  C J Niemegeers; J J Heykants; P A Janssen
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Fluphenazine pharmacokinetics and therapeutic response.

Authors:  M W Dysken; J I Javaid; S S Chang; C Schaffer; A Shahid; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Effect of a drug holiday on plasma chlorpromazine levels in chronic schizophrenic patients.

Authors:  L A Hershey; T Gift; R W Atkins; L Rivera-Calimlim
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 10.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.